December 10, 2019
1 min read
Save

Ocriplasmin effective for resolution of vitreomacular traction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A phase 4 multicenter study found nearly half of patients with vitreomacular traction, with or without macular hole, who received an intravitreal injection of ocriplasmin experienced resolution by day 28.

The OVIID-1 study included 466 patients with vitreomacular traction (VMT) with focal adhesion, without epiretinal membrane and with macular hole of 400 µm or less if present. Patients received a single intravitreal injection of Jetrea (ocriplasmin, ThromboGenics), and researchers evaluated the nonsurgical resolution of VMT by day 28, best corrected visual acuity, macular hole closure, vitrectomy rate and safety through 180 days.

By day 28, 47.4% of patients experienced nonsurgical resolution of VMT, of which 39.3% experienced resolution within the first week after the injection. The overall resolution rate by day 180 was 49.4%.

By days 28, 90 and 180, the mean gains in BCVA from baseline were 1.7, 3 and 3.5 letters, respectively. More patients with VMT resolution gained at least 5 or more letters in BCVA by day 28, 38.9% of patients, compared with 23.2% who experienced similar gains with no VMT resolution; at day 180, it was 52.6% vs. 29.9%, respectively.

Nonsurgical macular hole closure occurred in 39.5% of patients by day 28. This increased to 40.7% by day 90 and 41.9% by day 180. Researchers found 57.1% of patients with VMT and macular holes of 250 µm or less experienced macular hole closure compared with 27.5% of patients with VMT and macular holes between 250 µm and 400 µm by day 28.

The highest VMT resolution was observed in patients with macular holes of 250 µm or less at baseline, with 62.9% of patients experiencing closure. This subgroup also had a mean BCVA gain of 6.5 letters by day 180, as well. – by Robert Linnehan

Disclosures: Tadayoni reports he is a consultant for Alcon, ThromboGenics, Bausch + Lomb, Zeiss, Novartis, Bayer, Allergan, Alimera, Roche, Genentech, FCI and Thea. Please see the study for all other authors’ relevant financial disclosures.